Low dosage alpha-interferon treatment in patients with advanced cutaneous T-cell lymphoma
Related Experiment Video
Updated: Oct 13, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
H Hagberg1, L Juhlin, A Scheynius
1Department of Oncology, Akademiska Sjukhuset, Uppsala, Sweden.
Abstract:
Treatment with high dose (10-50 x 10(6) IU/m2 three times a week) of alpha-interferon (alpha-IFN) has been shown to induce remissions in about 50% of patients with cutaneous T-cell lymphoma. The optimal alpha-IFN dose, however, is not known. 4 patients with advanced cutaneous T-cell lymphoma were therefore treated with alpha-IFN in low doses of 2-4 x 10(6) IU/m2 three times a wk. 1 complete, 1 partial and 1 minor remission were observed. Skin biopsies before and during treatment were taken from 2 of the patients and showed improvement. Low doses of alpha-IFN can thus induce remission in patients with cutaneous T-cell lymphoma.
More Related Videos
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
08:33Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
Published on: June 25, 2019
Related Concept Videos
Tumor Immunotherapy
Inhibitors of Viral Protein Synthesis